Cellares is an Integrated Development and Manufacturing Organization (IDMO) - a category it claims to have pioneered - focused on automating the development and manufacture of cell therapies at industrial scale. Operating under current Good Manufacturing Practices (cGMP), the company builds and deploys hardware platforms, automated quality control systems, and integrated software designed to handle end-to-end cell therapy manufacturing workflows. Its customers and partners span academic institutions, biotechs, and pharmaceutical companies.
The company's core product is the Cell Shuttle™, a modular, cGMP-compliant platform built for walk-away, end-to-end automation of cell therapy manufacturing at industrial scale. Alongside it, Cell Q™ provides automated quality control for cell therapies, and an integrated software suite ties both hardware platforms into unified manufacturing and quality workflows. Together, these form the technology stack deployed across Cellares's network of Smart Factories.
Cellares applies Industry 4.0 principles - industrial automation and digitization - to what it characterises as a manufacturing challenge: producing cell therapies, which it frames as "living drugs," at the scale and cost required for broad patient access. The engineering and software work spans modular hardware design, manufacturing execution systems, automated QC, and the integration of these components into validated, regulated environments.
The company currently operates Smart Factories in South San Francisco and Bridgewater, with expansion into Europe and Japan planned. The team draws on backgrounds in biomanufacturing, biotech, and pharma.
